7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Brain Infarction D020520 17 associated lipids
Hirsutism D006628 3 associated lipids
Polycystic Ovary Syndrome D011085 14 associated lipids
Hypocalcemia D006996 12 associated lipids
Brain Ischemia D002545 89 associated lipids
Endocrine System Diseases D004700 4 associated lipids
Nerve Degeneration D009410 53 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Hypertension D006973 115 associated lipids
Periodontitis D010518 22 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Ermakov S et al. A significant association exists between receptor tyrosine kinase-like orphan receptor 2 gene variants and the OPG/RANKL ratio in human plasma. 2012 Osteoporos Int pmid:22057548
Baud'huin M et al. A soluble bone morphogenetic protein type IA receptor increases bone mass and bone strength. 2012 Proc. Natl. Acad. Sci. U.S.A. pmid:22761317
Terpos E et al. Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. 2011 Nov-Dec Clin. Exp. Rheumatol. pmid:22032557
Arikan F et al. C-telopeptide pyridinoline crosslinks of type I collagen, soluble RANKL, and osteoprotegerin levels in crevicular fluid of dental implants with peri-implantitis: a case-control study. 2011 Mar-Apr Int J Oral Maxillofac Implants pmid:21483881
Crespi R et al. Corticocancellous porcine bone in the healing of human extraction sockets: combining histomorphometry with osteoblast gene expression profiles in vivo. 2011 Jul-Aug Int J Oral Maxillofac Implants pmid:21841997
Franke S et al. Advanced glycation end products affect growth and function of osteoblasts. 2011 Jul-Aug Clin. Exp. Rheumatol. pmid:21906430
Rezg R et al. Inhibitors of vascular calcification as potential therapeutic targets. 2011 Jul-Aug J. Nephrol. pmid:21688249
Reyes-García R et al. [Cardiovascular disease and bone metabolism]. 2011 Aug-Sep Endocrinol Nutr pmid:21775224
Ostrowska Z et al. Circadian concentrations of free testosterone, selected markers of bone metabolism, osteoprotegerin and its ligand sRANKL in obese postmenopausal women. 2011 Postepy Hig Med Dosw (Online) pmid:22100799
Kurabayashi M [Bone and calcium update; diagnosis and therapy of bone metabolism disease update. Calcification of atherosclerotic plaques: mechanism and clinical significance]. 2011 Clin Calcium pmid:22133823
Tsioufis C et al. Relationships of osteoprotegerin with albuminuria and asymmetric dimethylarginine in essential hypertension: integrating vascular dysfunction. 2011 Expert Opin. Ther. Targets pmid:22136618
Zhou J et al. Expression of osteoprotegerin and receptor activator of nuclear factor κB ligand in root resorption induced by heavy force in rats. 2011 J Orofac Orthop pmid:22138776
Grzibovskis M et al. Specific signaling molecule expressions in the interradicular septum in different age groups. 2011 Stomatologija pmid:22071415
Chang YC and Zhao JH Effects of platelet-rich fibrin on human periodontal ligament fibroblasts and application for periodontal infrabony defects. 2011 Aust Dent J pmid:22126345
Plasilova M et al. Discordant gene expression signatures and related phenotypic differences in lamin A- and A/C-related Hutchinson-Gilford progeria syndrome (HGPS). 2011 PLoS ONE pmid:21738662
Ren G et al. Simultaneous administration of fluoride and selenite regulates proliferation and apoptosis in murine osteoblast-like MC3T3-E1 cells by altering osteoprotegerin. 2011 Biol Trace Elem Res pmid:21739163
Sylvester FA et al. Fecal osteoprotegerin may guide the introduction of second-line therapy in hospitalized children with ulcerative colitis. 2011 Inflamm. Bowel Dis. pmid:21744427
Weinstein RS et al. Osteoprotegerin prevents glucocorticoid-induced osteocyte apoptosis in mice. 2011 Endocrinology pmid:21771887
Lee JH et al. Tumor necrosis factor-α converting enzyme (TACE) increases RANKL expression in osteoblasts and serves as a potential biomarker of periodontitis. 2011 BMB Rep pmid:21777519
Baldi D et al. Dental implants osteogenic properties evaluated by cDNA microarrays. 2011 Implant Dent pmid:21778890
Kwan JS et al. Heritability of serum osteoprotegerin. 2011 Ann. Hum. Genet. pmid:21762114
Ibrahim T et al. Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients. 2011 Clin. Breast Cancer pmid:21764390
Yamamoto K et al. Effects of mechanical stress on cytokine production in mandible-derived osteoblasts. 2011 Oral Dis pmid:21771211
Chen WJ et al. Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men. 2011 Cardiovasc Diabetol pmid:21771299
Nakashima A et al. Plasma osteoprotegerin, arterial stiffness, and mortality in normoalbuminemic Japanese hemodialysis patients. 2011 Osteoporos Int pmid:20812007
Chen WF et al. Total flavonoid fraction of the Herba epimedii extract suppresses urinary calcium excretion and improves bone properties in ovariectomised mice. 2011 Br. J. Nutr. pmid:20815976
Zinonos I et al. Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo. 2011 J. Bone Miner. Res. pmid:20818644
Loncar G et al. Association of increased parathyroid hormone with neuroendocrine activation and endothelial dysfunction in elderly men with heart failure. 2011 J. Endocrinol. Invest. pmid:20820131
Tao H et al. P38 mitogen-activated protein kinase inhibitor, FR167653, inhibits parathyroid hormone related protein-induced osteoclastogenesis and bone resorption. 2011 PLoS ONE pmid:21886782
Markatseli AE et al. Association of the A1330V and V667M polymorphisms of LRP5 with bone mineral density in Greek peri- and postmenopausal women. 2011 Maturitas pmid:21840657
Kauther MD et al. Calcitonin substitution in calcitonin deficiency reduces particle-induced osteolysis. 2011 BMC Musculoskelet Disord pmid:21843355
Gradosova I et al. The role of atorvastatin in bone metabolism in male albino Wistar rats. 2011 Pharmazie pmid:21901984
Straface G et al. Assessment of the genetic effects of polymorphisms in the osteoprotegerin gene, TNFRSF11B, on serum osteoprotegerin levels and carotid plaque vulnerability. 2011 Stroke pmid:21903966
Tripathi A et al. Bisphosphonate therapy for skeletal malignancies and metastases: impact on jaw bones and prosthodontic concerns. 2011 J Prosthodont pmid:21883630
Wattanaroonwong N et al. Oestrogen inhibits osteoclast formation induced by periodontal ligament fibroblasts. 2011 Arch. Oral Biol. pmid:21035111
D'Amelio P et al. Bone and bone marrow pro-osteoclastogenic cytokines are up-regulated in osteoporosis fragility fractures. 2011 Osteoporos Int pmid:21116815
Giner M et al. Alendronate and raloxifene affect the osteoprotegerin/RANKL system in human osteoblast primary cultures from patients with osteoporosis and osteoarthritis. 2011 Eur. J. Pharmacol. pmid:21050847
Belibasakis GN et al. Porphyromonas gingivalis induces RANKL in T-cells. 2011 Inflammation pmid:20446027
Toffoli B et al. Osteoprotegerin promotes vascular fibrosis via a TGF-β1 autocrine loop. 2011 Atherosclerosis pmid:21679949
de Moraes M et al. Comparative immunohistochemical expression of RANK, RANKL and OPG in radicular and dentigerous cysts. 2011 Arch. Oral Biol. pmid:21683340
Ndip A et al. The RANKL/RANK/OPG signaling pathway mediates medial arterial calcification in diabetic Charcot neuroarthropathy. 2011 Diabetes pmid:21659498
Gulseren A et al. Evaluation of weekly risedronate treatment in postmenopausal women with osteoprotegerin. 2011 Panminerva Med pmid:21659972
Corallini F et al. Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells. 2011 J. Cell. Physiol. pmid:21660951
Costa-Rodrigues J and Fernandes MH Paracrine-mediated differentiation and activation of human haematopoietic osteoclast precursor cells by skin and gingival fibroblasts. 2011 Cell Prolif. pmid:21535267
Lee YS and Choi EM Apocynin stimulates osteoblast differentiation and inhibits bone-resorbing mediators in MC3T3-E1 cells. 2011 Cell. Immunol. pmid:21683946
Schoppet M et al. Crystallizing nanoparticles derived from vascular smooth muscle cells contain the calcification inhibitor osteoprotegerin. 2011 Biochem. Biophys. Res. Commun. pmid:21371424
Pobeha P et al. Relationship between osteoporosis and adipose tissue leptin and osteoprotegerin in patients with chronic obstructive pulmonary disease. 2011 Bone pmid:21376149
Krause U et al. Assays of osteogenic differentiation by cultured human mesenchymal stem cells. 2011 Methods Mol. Biol. pmid:21431522
Clemens TL and Karsenty G The osteoblast: an insulin target cell controlling glucose homeostasis. 2011 J. Bone Miner. Res. pmid:21433069
Cao H et al. Dysregulated atrial gene expression of osteoprotegerin/receptor activator of nuclear factor-κB (RANK)/RANK ligand axis in the development and progression of atrial fibrillation. 2011 Circ. J. pmid:22001292
Scialla JJ et al. Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease. 2011 Clin J Am Soc Nephrol pmid:21940840
Sfiridaki K et al. Angiogenesis-related cytokines, RANKL, and osteoprotegerin in multiple myeloma patients in relation to clinical features and response to treatment. 2011 Mediators Inflamm. pmid:21941412
Bao L et al. Anthraquinone compounds from Morinda officinalis inhibit osteoclastic bone resorption in vitro. 2011 Chem. Biol. Interact. pmid:21945525
Zhou XW et al. [Expressions of RANK, RANKL, and osteoprotegerin in male rats at different ages]. 2011 Nan Fang Yi Ke Da Xue Xue Bao pmid:21945761
Carmona-Fernandes D et al. Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients. 2011 Arthritis Res. Ther. pmid:22027240
Wang Y et al. [Interleukin-4 and osteoprotegerin suppress polyethylene wear debris-induced osteolysis in a murine air pouch model]. 2011 Nan Fang Yi Ke Da Xue Xue Bao pmid:22027773
Wang JZ et al. [Effect of Epimedium extract on osteoprotegerin and RANKL mRNA expressions in glucocorticoid-induced femoral head necrosis in rats]. 2011 Nan Fang Yi Ke Da Xue Xue Bao pmid:22027774
Ferrari-Lacraz S and Ferrari S Do RANKL inhibitors (denosumab) affect inflammation and immunity? 2011 Osteoporos Int pmid:20571772
Goto H et al. Human bone marrow adipocytes support dexamethasone-induced osteoclast differentiation and function through RANKL expression. 2011 Biomed. Res. pmid:21383509
Belibasakis GN et al. The RANKL-OPG system is differentially regulated by supragingival and subgingival biofilm supernatants. 2011 Cytokine pmid:21474331
Siomou E et al. Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease. 2011 Pediatr. Nephrol. pmid:21479768
Sexton WM et al. Salivary biomarkers of periodontal disease in response to treatment. 2011 J. Clin. Periodontol. pmid:21480939
Cordeiro MM et al. Primary teeth show less protecting factors against root resorption. 2011 Int J Paediatr Dent pmid:21481035
Kaneuji T et al. Mechanisms involved in regulation of osteoclastic differentiation by mechanical stress-loaded osteoblasts. 2011 Biochem. Biophys. Res. Commun. pmid:21459078
Luvizuto ER et al. Raloxifene therapy inhibits osteoclastogenesis during the alveolar healing process in rats. 2011 Arch. Oral Biol. pmid:21536255
Al-Dujaili SA et al. Apoptotic osteocytes regulate osteoclast precursor recruitment and differentiation in vitro. 2011 J. Cell. Biochem. pmid:21538477
Stępień E et al. Increased levels of bone remodeling biomarkers (osteoprotegerin and osteopontin) in hypertensive individuals. 2011 Clin. Biochem. pmid:21539822
Hall J et al. A controlled clinical exploratory study on genetic markers for peri-implantitis. 2011 Eur J Oral Implantol pmid:22282733
Xu ML et al. [An update for the research progress of osteoprotegerin on coronary artery disease]. 2011 Zhonghua Xin Xue Guan Bing Za Zhi pmid:22321243
de Souza Faloni AP et al. Jaw and long bone marrows have a different osteoclastogenic potential. 2011 Calcif. Tissue Int. pmid:20862464
Park JS et al. Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus. 2011 Eur. J. Endocrinol. pmid:20961967
Karosi T et al. Osteoprotegerin expression and sensitivity in otosclerosis with different histological activity. 2011 Eur Arch Otorhinolaryngol pmid:20963600
Halade GV et al. Obesity-mediated inflammatory microenvironment stimulates osteoclastogenesis and bone loss in mice. 2011 Exp. Gerontol. pmid:20923699
Kassi E et al. Effects of Sideritis euboea (Lamiaceae) aqueous extract on IL-6, OPG and RANKL secretion by osteoblasts. 2011 Nat Prod Commun pmid:22224290
Chang YH et al. Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing-ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy. 2011 Metab. Clin. Exp. pmid:21251686
Benslimane-Ahmim Z et al. Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties. 2011 J. Thromb. Haemost. pmid:21255246
WaluÅ›-Miarka M et al. Osteoprotegerin is associated with markers of atherosclerosis and body fat mass in type 2 diabetes patients. 2011 Int. J. Cardiol. pmid:21255853
Saito CT et al. Effect of low-level laser therapy on the healing process after tooth replantation: a histomorphometrical and immunohistochemical analysis. 2011 Dent Traumatol pmid:21244626
Erkol A et al. Relation of circulating osteoprotegerin levels on admission to microvascular obstruction after primary percutaneous coronary intervention. 2011 Am. J. Cardiol. pmid:21247537
Sobue T et al. Murine TMJ loading causes increased proliferation and chondrocyte maturation. 2011 J. Dent. Res. pmid:21248355
Ribeiro FV et al. Cytokines and bone-related factors in systemically healthy patients with chronic periodontitis and patients with type 2 diabetes and chronic periodontitis. 2011 J. Periodontol. pmid:21284550
Vik A et al. Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromsø Study. 2011 J. Thromb. Haemost. pmid:21284802
Hasegawa T et al. [Animal models for bone and joint disease. Bone disease of osteoprotegerin deficient mouse]. 2011 Clin Calcium pmid:21289415
Kawaguchi H [Approach for therapeutic targets of osteoarthritis]. 2011 Nippon Yakurigaku Zasshi pmid:21747205
Hou WW et al. Involvement of Wnt activation in the micromechanical vibration-enhanced osteogenic response of osteoblasts. 2011 J Orthop Sci pmid:21833614
Watkins M et al. Osteoblast connexin43 modulates skeletal architecture by regulating both arms of bone remodeling. 2011 Mol. Biol. Cell pmid:21346198
Confavreux CB Bone: from a reservoir of minerals to a regulator of energy metabolism. 2011 Kidney Int. Suppl. pmid:21346725
Caetano-Lopes J et al. Upregulation of inflammatory genes and downregulation of sclerostin gene expression are key elements in the early phase of fragility fracture healing. 2011 PLoS ONE pmid:21347301
Assmann G et al. Genetic variations in the genes encoding receptor activator nuclear factor κ B (RANK), receptor activator nuclear factor κ B ligand (RANKL) and osteoprotegerin (OPG) in patients with psoriasis and psoriatic arthritis: a case-control study. 2011 J. Dermatol. pmid:21352301
Audo R et al. Mechanisms and clinical relevance of TRAIL-triggered responses in the synovial fibroblasts of patients with rheumatoid arthritis. 2011 Arthritis Rheum. pmid:21305500
Alexander KA et al. Osteal macrophages promote in vivo intramembranous bone healing in a mouse tibial injury model. 2011 J. Bone Miner. Res. pmid:21305607
Lau CP et al. Pamidronate, farnesyl transferase, and geranylgeranyl transferase-I inhibitors affects cell proliferation, apoptosis, and OPG/RANKL mRNA expression in stromal cells of giant cell tumor of bone. 2011 J. Orthop. Res. pmid:20886653
Jabbar S et al. Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis. 2011 J. Clin. Pathol. pmid:21307155
Maïmoun L et al. In peripubertal girls, artistic gymnastics improves areal bone mineral density and femoral bone geometry without affecting serum OPG/RANKL levels. 2011 Osteoporos Int pmid:21359671
Polzer K et al. Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis. 2011 Arthritis Rheum. pmid:21360496
Oshita K et al. Human mesenchymal stem cells inhibit osteoclastogenesis through osteoprotegerin production. 2011 Arthritis Rheum. pmid:21360521
Ignatius A et al. Complement C3a and C5a modulate osteoclast formation and inflammatory response of osteoblasts in synergism with IL-1β. 2011 J. Cell. Biochem. pmid:21598302
Sun CX et al. [Patterns of osteoprotegerin or nuclear factor kappa B ligand gene expression in the treatment of bone defect with bone marrow stem cell transplantation and low-frequency vibration]. 2011 Zhonghua Yi Xue Za Zhi pmid:21600122
Liu ZF et al. [Effect of ultrasound on osteoprotegerin and receptor activator nuclear factor kappaB ligand expression during root resorption in rats]. 2011 Nan Fang Yi Ke Da Xue Xue Bao pmid:21602131
Blázquez-Medela AM et al. Osteoprotegerin and diabetes-associated pathologies. 2011 Curr. Mol. Med. pmid:21568931

Table of Content